XNAS · Healthcare · Biotechnology
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.28 | -0.35 | -25.00% | $10.3M | ❌ Miss | -1.18% | -0.62% | — |
| 2026-05-07 | Q1 2026 | -0.52 | -0.39 | +25.00% | $3.7M | ✅ Beat | +0.00% | -1.03% | -8.12% |
| 2026-02-26 |
| Q4 2025 |
| -0.64 |
| -0.51 |
| +20.31% |
| $0 |
| mixed |
| -1.74% |
| +1.23% |
| -4.49% |
| 2025-11-06 | Q3 2025 | -0.61 | -0.39 | +36.07% | $10.0M | ✅ Beat | — | — | — |
| 2025-02-27 | Q4 2024 | -0.45 | -0.36 | +20.00% | $0 | ✅ Beat | +2.75% | -3.94% | -15.65% |
| 2024-08-07 | Q2 2024 | -0.31 | -0.11 | +64.52% | $8.9M | ✅ Beat | +3.40% | +13.83% | +16.92% |
| 2024-05-07 | Q1 2024 | -0.33 | -0.30 | +9.09% | $1.3M | ✅ Beat | -9.97% | -22.10% | -30.75% |
| 2024-03-08 | Q4 2023 | -0.40 | -0.25 | +37.50% | $2.5M | ✅ Beat | — | — | — |
Showing last 8 quarters.